Dexamethasone

BreastfeedingPediatric
  • TRADE NAMES: Cortastat; Decadron (Merck); Dexone (Solvay); Hexadrol; Ozurdex (Allergan)
  • INDICATIONS: Antiemetic, arthralgias, dermatoses, diagnostic aid, macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), non-infectious uveitis affecting the posterior segment of the eye
  • CLASS: Antiemetic, Corticosteroid, systemic, Corticosteroid, topical, COVID-19 putative drug
  • HALF-LIFE: N/A

Acneiform eruption / acneiform dermatitis 

(2016): Navari RM, Expert Opin Drug Saf 15(3), 343 [REVIEW]

(2016): Yanaranop M+, Asia Pac J Clin Oncol 12(3), 2892–11%

(2015): Gupta N+, J Hematol Oncol 8, 103 (1 case) (with lenalidomide and ixazomib)

(2006): Mentink LF+, Arch Dermatol 142(5), 570

(2006): Vardy J+, Br J Cancer 94(7), 101115%

(1997): Borgna-Pignatti+, J Pediatr 130(1), 13-6

Acute generalized exanthematous pustulosis (AGEP) 

(2009): Momin SB+, Cutis 83(6), 291 (with meloxicam and thalidomide)

(1995): Demitsu T+, Dermatology 193, 56

Anaphylactoid reactions / anaphylaxis 

(2012): Lonial S+, J Clin Oncol 30(16), 1953 (1 case) (with elotuzumab and lenalidomide)

(2009): Shirahata A+, Gan To Kagaku Ryoho 36 (8), 1383

(1997): Figueredo E+, Allergy 52(8), 877

Burning 

(2018): Dylla L+, Prehosp Emerg Care Feb, Epub ahead of print

Candidiasis 

(2002): Pera A+, J Perinatol 22(3), 204

Cushingoid features 

(2017): Mitsuhashi A+, Am J Clin Oncol 40(2), 118 (5 cases) (with palonosetron)

Dermatitis 

(2003): Hall VC+, J Am Acad Dermatol 48(4), 548 (with thalidomide)

(2002): Nucera E+, Dermatology 204(3), 248

(2000): Chew AL+, Cutis 65, 307

(1994): Whitmore SE, Br J Dermatol 131, 296 (generalized)

(1989): Rivara G+, Contact Dermatitis 21(2), 83-9 [REVIEW]

Ecchymoses 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

Edema 

(2017): Palladini G+, Blood 129(15), 2120 (with pomalidomide)

(2012): Kumar SK+, Blood 119(21), 4860 (with cyclophosphamide and lenalidomide)

(2011): Hus M+, Ann Hematol 90(10), 11615% (with thalidomide)

(1998): Berinstein TH+, Ear Nose Throat J 77(1), 40-3

Embolia cutis medicamentosa (Nicolau syndrome) 

(1997): Kohler LD+, Int J Dermatol 36(3), 197 (with diclofenac)

Erythema 

(2015): Yoshida Y+, Drug Des Devel Ther 9, 60674% (with oxaliplatin)

Erythema multiforme 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2003): Hall VC+, J Am Acad Dermatol 48(4), 548 (with thalidomide)

(1999): Alexiou C+, Laryngorhinootologie 78(10), 573

Exanthems 

(2015): Gupta N+, J Hematol Oncol 8, 103 (7 cases) (with lenalidomide and ixazomib)

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2010): Subedi BH+, Wilderness Environ Med 21(4), 345

(1987): Maucher OM+, Hautarzt (German) 38, 577

Exfoliative dermatitis 

(2015): Gupta N+, J Hematol Oncol 8, 103 (2 cases) (with lenalidomide and ixazomib)

Exfoliative erythroderma 

(2003): Hall VC+, J Am Acad Dermatol 48(4), 548 (with thalidomide)

Flushing 

(2015): El Abd O+, Pain Physician 18(3), 277

(2006): Mentink LF+, Arch Dermatol 142(5), 570

(2002): Toth GG+, J Eur Acad Dermatol Venereol 16(6), 607

(1999): Alexiou C+, Laryngorhinootologie 78(10), 573

(1999): Toth GG+, Ther Drug Monit 21(5), 532

Herpes zoster 

(2016): Shimazaki C+, Int J Hematol 103(1), 79 (grade 3 / 1 case) (with bortezomib and melphalan)

(2015): Tsukada N+, Rinsho Ketsueki 56(8), 1069 (grade 3 / 2 cases) (reactivation / with bortezomib and cyclophosphamide)

Hyperhidrosis 

(2015): Gupta N+, J Hematol Oncol 8, 103 (1 case) (with lenalidomide and ixazomib)

(2012): Lonial S+, J Clin Oncol 30(16), 195311% (with elotuzumab and lenalidomide)

Hypersensitivity 

(2016): Yamamoto T+, Eur J Gynaecol Oncol 37(6), 83352–54% (with paclitaxel and aprepitant)

(2015): Yoshida Y+, Drug Des Devel Ther 9, 60674% (with oxaliplatin)

(2011): Hus M+, Ann Hematol 90(10), 11615% (with thalidomide)

(1993): Chan AT, BMJ 306, 109

(1993): Williams WR, BMJ 306(6877), 585

(1986): Baldinger J+, Ann Ophthalmol eact(3), 95-6 (with polymyxin B/neomycin)

Necrotizing fasciitis 

(2014): Mondello P+, Springerplus 3, 123 [REVIEW] (with ibandronate and lenalidomide)

Pellagra 

(2010): Yokomizo Y+, Hinyokika Kiyo 56(10), 585 (with docetaxel and estramustine)

Peripheral edema 

(2020): Palladini G+, Blood Apr, Epub ahead of print50% (with daratumumab, cyclophosphamide and bortezomib)

(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)

(2016): Mateos MV+, Br J Haematol 175(3), 44825% (grade 3+) (with elotuzumab and thalidomide)

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2015): Usmani SZ+, Blood Cancer J 5, e33483% (with bortezomib, elotuzumab and lenalidomide)

(2013): Wang M+, Blood 122(18), 312237% (with carfilzomib and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195325% (with elotuzumab and lenalidomide)

(2002): Hempen C+, Support Care Cancer 10(4), 322

(1991): Weissman DE+, J Neurooncol 11(3), 235

Photosensitivity 

(1988): Stierstorfer MB+, Arch Dermatol 124(12), 1870

Pigmentation 

(2015): Gupta N+, J Hematol Oncol 8, 103 (6 cases) (with lenalidomide and ixazomib)

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

Pruritus (itching) 

(2015): Gupta N+, J Hematol Oncol 8, 103 (10 cases) (with lenalidomide and ixazomib)

(2004): Crandell JT, Can J Anaesth 51(4), 398

(2004): Kuczkowski KM, Anaesthesia 59(3), 308

(2003): Perron G+, Can J Anaesth 50(7), 749

(2001): Dong Y+, Chin Med J (Engl) 114(7), 764 (with methotrexate)

(1999): Alexiou C+, Laryngorhinootologie 78(10), 573

(1988): Taleb N+, Eur J Cancer Clin Oncol 24(3), 495

Pruritus ani et vulvae 

(2015): El Abd O+, Pain Physician 18(3), 2774%

(2012): Gu CY+, Pharmazie 67(12), 1015

Rash 

(2018): Li CS+, Zhongguo Shi Yan Xue Ye Xue Za Zhi 26(3), 836 (with bortezomib and thalidomide)

(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)

(2016): Liu HB+, Zhongguo Shi Yan Xue Ye Xue Za Zhi (Chinese) 24(2), 498 (5 cases) (with lenalidomide)

(2016): Mateos MV+, Lancet Oncol 175(3), 4483% (grade 3) (with lenalidomide)

(2015): Kim HJ+, Blood Res 50(1), 7 [REVIEW] (with lenalidomide)

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2014): Wang YS+, Sichuan Da Xue Xue Bao Yi Xue Ban (Chinese) 45(3), 52967% (with bortezomib and thalidomide)

(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195311% (with elotuzumab and lenalidomide)

(2010): Subedi BH+, Wilderness Environ Med 21(4), 345

(2003): Jain R+, J Dermatol 30(10), 713 (3 cases) (with cyclophosphamide)

Seborrheic dermatitis 

(2003): Hall VC+, J Am Acad Dermatol 48(4), 548 (with thalidomide)

Septic–toxic shock 

(2017): Kwon J+, Cancer Med 6(1), 100 (fatal / 2 cases)Fatal (with cyclophosphamide and thalidomide)

Stevens-Johnson syndrome 

(2012): Siniscalchi A+, Support Care Cancer 20(7), 1585 (with lenalidomide)

Striae 

(1997): Borgna-Pignatti C+, J Pediatr 130(1), 13-6

(1992): Pang S+, J Clin Endocrinol 75(1), 249

(1985): Job JC+, Arch Fr Pediatr 42(9), 765

(1983): Guest G+, Arch Fr Pediatr 40(6), 453

Toxic epidermal necrolysis 

(2003): Hall VC+, J Am Acad Dermatol 48(4), 548 (with thalidomide)

Toxicity 

(2016): Pan Z+, Int J Cancer 139(8), 186420% (grade 3 or 4) (with methotrexate and radiotherapy)

(2014): Rasche L+, Ann Hematol 93(7), 1207 (with carmustine, cytarabine, etoposide and melphalan)

(2012): Khan ML+, Br J Haematol 156(3), 326 (with bortezomib, cyclophosphamide and lenalidomide)

(2011): Kumar SK+, Am J Hematol 86(8), 640 (with cyclophosphamide and lenalidomide)

(2003): Belgaumi AF+, Cancer 97(11), 2898 (with daunomycin)

Urticaria 

(1995): Valdivieso R+, J Investig Allergol Clin Immunol 5(3), 171 (2 cases) (with paramethasone)

Xerosis 

(2015): Gupta N+, J Hematol Oncol 8, 103 (4 cases) (with lenalidomide and ixazomib)

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

Abnormal hair growth 

(2015): Gupta N+, J Hematol Oncol 8, 103 (1 case) (with lenalidomide and ixazomib)

Alopecia 

(2003): Jain R+, J Dermatol 30(10), 7139% (with cyclophosphamide)

Hirsutism 

(1997): Borgna-Pignatti+, J Pediatr 130(1), 13-6

Hypertrichosis 

(2006): Mentink LF+, Arch Dermatol 142(5), 570

Mucositis 

(2016): Pan Z+, Int J Cancer 139(8), 1864 (with methotrexate and radiotherapy)

Oral candidiasis 

(2001): Hardy JR+, Palliat Med 15(1), 3-8

(1983): Hanks GW+, Postgrad Med J 59(697), 702

Xerostomia (dry mouth) 

(2017): Zadik Y+, Expert Opin Pharmacother 18(3), 235

Arrhythmias 

(1998): Hari P+, Indian J Pediatr 65(4), 557 [REVIEW]

Bradycardia 

(2018): Sing EPC+, J Pediatr Hematol Oncol Apr, Epub ahead of print46%

(2015): Stroeder J+, Can Pharm J (Ott) 148(5), 235 [REVIEW]

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2013): Dossabhoy NR+, J La State Med Soc 165(5), 283

(2013): Marinov M+, Br J Anaesth 111(6), 1025

(2011): Hus M+, Ann Hematol 90(10), 11615% (with thalidomide)

(2005): Palladini G+, Blood 105(7), 294926% (with thalidomide)

(1988): Ohlsson A+, Lancet 2(8619), 1074

(1988): Puntis JW+, Lancet 2(8624), 1372

Cardiac failure 

(2018): Siegel DS+, J Clin Oncol Jan, Epub ahead of print2% (grade 3+) (with lenalidomide)

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

Cardiotoxicity 

(2018): Siegel DS+, J Clin Oncol Jan, Epub ahead of print2% (grade 3+) (with lenalidomide)

(2014): Atalay F+, J Med Case Rep 8, 252 (with cyclophosphamide, doxorubicin, rituximab and vincristine)

Hypertension 

(2018): Siegel DS+, J Clin Oncol Jan, Epub ahead of print2% (grade 3+) (with lenalidomide)

(2018): Sing EPC+, J Pediatr Hematol Oncol Apr, Epub ahead of print52%

(2016): Berenson JR+, Blood 127(26), 33607% (grade 3+) (with carfilzomib)

(2016): Dimopoulos MA+, Lancet Oncol 17(1), 273–9% (grade 3+) (with bortezomib or carfilzomib)

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2006): Mentink LF+, Arch Dermatol 142(5), 570

(2006): Wallenborn J+, BMJ 333(7563), 324 (with metoclopramide)

(2003): Halliday HL+, Cochrane Database Syst (1), CD001146 [REVIEW]

(2003): Jain R+, J Dermatol 30(10), 7133% (with cyclophosphamide)

(2001): Halliday HL+, Pediatrics 107(2), 232

(1999): Fuchs M+, HNO 47(7), 647

(1998): Hari P+, Indian J Pediatr 65(4), 557 [REVIEW]

(1996): Smets K+, Eur J Pediatr 155(7), 573

(1995): Caulier MT+, Br J Haematol 91(2), 477

(1992): Greenough A+, Eur J Pediatr 151(2), 134

(1992): Pang S+, J Clin Endocrinol Metab 75(1), 249

(1990): Ferrara TB+, J Perinatol 10(2), 137

(1989): Merz U+, Klin Padiatr 201(1), 11-5

Hypotension 

(2013): Richardson PG+, Blood 122(14), 233120% (with bortezomib and panobinostat)

Myocardial toxicity 

(2005): Balys R+, Int J Pediatr Otorhinolaryngol 69(2), 271

(2003): Halliday HL+, Cochrane Database Syst Rev (1), CD001146 [REVIEW]

(2003): Lilien LD+, Pediatr Cardiol 24(3), 280

(2000): Takagi S+, Jpn Circ J 64(10), 785

(1998): Fritz KI+, J Perinatol 18(1), 38-4 [REVIEW]

(1998): Kothari SN+, Surgery 123(1), 102

(1997): Boeuf B+, Arch Pediatr 4(2), 152 [REVIEW]

(1997): Miranda-Mallea J+, Eur J Pediatr 156(5), 394

(1996): Villa Alcazar M+, An Esp Pediatr 44(4), 393 [REVIEW]

(1995): Haney I+, Am J Perinatol 12(4), 271

(1995): Pokela ML, Duodecim 111(14), 1310

Orthostatic hypotension 

(2014): Mostaghel EA, Cancer Manag Res 6, 39 [REVIEW]2% (with abiraterone)

Pericardial effusion 

(2014): Benjamini O+, Am J Hematol 89(3), 282 (grade 3 or 4) (in hyper CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone) plus dasatinib)

Tachycardia 

(2006): Wallenborn J+, BMJ 333(7563), 324 (with metoclopramide)

(2005): Balys R+, Int J Pediatr 69(2), 271

Thromboembolism 

(2017): Maharaj S+, Expert Rev Anticancer Ther 17(7), 585 [REVIEW] (arterial / with lenalidomide)

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2011): Hus M+, Ann Hematol 90(10), 11615% (with thalidomide)

Venous thromboembolism 

(2015): Kim HJ+, Blood Res 50(1), 7 [REVIEW] (with lenalidomide)

(2014): Baz RC+, Am J Hematol 89(1), 629% (grade 3 or 4) (with doxorubicin and lenalidomide)

(2013): Fouquet G+, Cancer 119(20), 368020% (with lenalidomide)

(2013): Mateos MV+, N Engl J Med 369(5), 4382–3% (grade 1–2) (with lenalidomide)

(2012): Chanan-Khan AA+, Int J Hematol 96(2), 254 (with lenalidomide)

Agitation 

(2016): Navari RM, Expert Opin Drug Saf 15(3), 343 [REVIEW]

Altered mental status 

(2010): Subedi BH+, Wilderness Environ Med 21(4), 345

Anorexia 

(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)

(2014): Hamada S+, Support Care Cancer 22(8), 21613% (with aprepitant and palonosetron)

Anxiety 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

Catatonia 

(2016): Vanstechelman S+, Acta Clin Belg 71(6), 438

(2011): Dada MU+, Afr J Psychiatry (Johannesbg) 14(4), 316

Confusion 

(2014): Richardson PG+, Blood 123(12), 18263% (grade 3 or 4) (with pomalidomide)

Depression 

(2016): Hatano Y+, BMJ Support Palliat Care 6(3), 331

Dysgeusia (taste perversion) 

(2005): Herr BD+, Otolaryngol Head Neck Surg 132(4), 527

(2003): Jain R+, J Dermatol 30(10), 71313% (with cyclophosphamide)

(1993): Pasricha JS+, Int J Dermatol 32(10), 753

Euphoria 

(2016): Hatano Y+, BMJ Support Palliat Care 6(3), 331

Fever (pyrexia) 

(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2013): Wang M+, Blood 122(18), 312244% (with carfilzomib and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195329% (with elotuzumab and lenalidomide)

(2011): Hus M+, Ann Hematol 90(10), 11612% (with thalidomide)

(1997): McIntyre PB+, JAMA 278(11), 925

(1994): Pichard E+, Isr J Med Sci 30(5-6), 408

Headache <5%

(2015): El Abd O+, Pain Physician 18(3), 277

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2012): Lonial S+, J Clin Oncol 30(16), 195321% (with elotuzumab and lenalidomide)

(2003): Jain R+, J Dermatol 30(10), 71316% (with cyclophosphamide)

(2001): Dong Y+, Chin Med J (Engl) 114(7), 764 (with methotrexate)

(1998): Goedhals L+, Ann Oncol 9(6), 661 (with granisetron)

(1998): Martoni A+, Anticancer Res 18(4B), 2799 (with granisetron)

(1993): Pasricha JS+, Int J Dermatol 32(10), 753

Hypoesthesia (numbness) 

(2015): El Abd O+, Pain Physician 18(3), 27712%

Insomnia 

(2016): Hatano Y+, BMJ Support Palliat Care 6(3), 331

(2016): Navari RM, Expert Opin Drug Saf 15(3), 343 [REVIEW]

(2015): El Abd O+, Pain Physician 18(3), 277

(2015): Gupta N+, J Hematol Oncol 8, 10312% (with lenalidomide and ixazomib)

(2015): Ocio EM+, Haematologica 100(7), e289 (with panobinostat)

(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)

(2014): Roila F+, J Clin Oncol 32(2), 1013%

(2013): Wang M+, Blood 122(18), 312235% (with carfilzomib and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195329% (with elotuzumab and lenalidomide)

Irritability 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

Leukoencephalopathy 

(2009): Nguyen MT+, J Clin Neurosci 16(12), 1688 (with Cisplatin)

(2006): Pandey R+, Leuk Lymphoma 47(7), 1431 (with thalidomide)

Memory loss/memory impaired 

(2013): Edelmann MN+, Pediatr Blood Cancer 60(11), 1778

Mood changes 

(2018): Sing EPC+, J Pediatr Hematol Oncol Apr, Epub ahead of print9%

Neurotoxicity 

(2017): Berdeja JG+, Br J Haematol 177(2), 254 (with bendamustine and bortezomib)

(2016): Levinsen M+, J Pediatr Hematol Oncol 38(8), 60222% (with cytarabine)

(2016): Pan Z+, Int J Cancer 139(8), 1864 (with methotrexate and radiotherapy)

(2016): Warris LT+, J Clin Oncol 34(19), 2287Pediatric

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (1 case) (with oxaliplatin)

(2014): Leiba M+, Br J Haematol 166 (5), 702 [REVIEW]11% (grade 3 or 4) (with bortezomib and thalidomide)

(2014): Richardson PG+, Blood 123(10), 146153% (with bortezomib and lenalidomide)

(2012): Chanan-Khan AA+, Int J Hematol 96(2), 254 (with lenalidomide)

(2011): Hus M+, Ann Hematol 90(10), 116124% (with thalidomide)

(2010): Richardson PG+, Blood 116(5), 67980% (with lenalidomide and bortezomib)

Pain 

(2015): El Abd O+, Pain Physician 18(3), 277

Paresthesias 

(2015): El Abd O+, Pain Physician 18(3), 27712%

(1986): Rasche H+, Dtsch Med Wochenschr 111(37), 1406

Peripheral neuropathy 

(2020): Terpos E+, Ann Hematol Apr, Epub ahead of print35% (3% grade 3–4) (with ixazomib and lenalidomide)

(2018): Hansen VL+, Clin Lymphoma Myeloma Leuk Mar, Epub ahead of print15% (with bortezomib (SC administered) and panobinostat)

(2018): Iida S+, Cancer Sci Feb, Epub ahead of print9–23% (grade 3 or 4) (with bortezomib or thalidomide)

(2018): Li CS+, Zhongguo Shi Yan Xue Ye Xue Za Zhi 26(3), 836 (with bortezomib and thalidomide)

(2018): Siegel DS+, J Clin Oncol Jan, Epub ahead of print3% (grade 3+) (with lenalidomide)

(2018): Sonbol MB+, Leuk Lymphoma Jan, Epub ahead of print24% (grade 3+) (with bortezomib, cyclophosphamide and rituximab)

(2018): Terpos E+, Eur J Haematol 100(1), 1023–37% (with bortezomib)

(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)

(2017): Zhang YP+, Eur J Haematol 99(6), 48960% (with bortezomib)

(2016): Richardson PG+, Expert Rev Clin Pharmacol 9(1), 35 [REVIEW]61% (grade 3 or 4) (with bortezomib and panobinostat)

(2016): Shimazaki C+, Int J Hematol 103(1), 7916% (with bortezomib and melphalan)

(2015): Gupta N+, J Hematol Oncol 8, 10326% (with lenalidomide and ixazomib)

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2015): Shah JJ+, Blood 126(20), 2284 (with carfilzomib and pomalidomide)

(2015): Usmani SZ+, Blood Cancer J 5, e33483% (with bortezomib, elotuzumab and lenalidomide)

(2014): Bringhen S+, Blood 124(1), 639% (grade 1 or 2) (with carfilzomib and cyclophosphamide)

(2014): Cook G+, Lancet Oncol 15(8), 87412% (with bortezomib and doxorubicin)

(2014): Craig M+, Br J Haematol 166(6), 920 (with bortezomib, cyclophosphamide, prednisone and rituximab)

(2014): San-Miguel JF+, Lancet Oncol 15(11), 119515% (grade 3 or 4) (with bortezomib)

(2014): Wang YS+, Sichuan Da Xue Xue Bao Yi Xue Ban (Chinese) 45(3), 5297% (grade 3) (with bortezomib and thalidomide)

(2014): Zhang Y+, Pathol Oncol Res 20(4), 9878–33% (with bortezomib and doxorubicin)

(2013): Dimopoulos MA+, Blood 122(19), 327646% (with bortezomib and rituxuimab)

(2013): Richardson PG+, Blood 122(14), 2331 (grade 3 / 1 case) (with bortezomib and panobinostat)

(2013): Voorhees PM+, Blood 121(5), 858 (with bortezomib and lenalidomide)

(2013): Wang M+, Blood 122(18), 312227% (with carfilzomib and lenalidomide)

(2012): Berenson JR+, Leukemia 26(7), 167525% (with bortezomib, doxorubicin and lenalidomide)

(2012): Jakubowiak AJ+, Blood 120(9), 180123% (low-dose / with carfilzomib and lenalidomide)

(2012): Kumar S+, Blood 119(19), 4375 (with bortezomib, cyclophosphamide and lenalidomide)

Psychosis 

(2019): Fischer M+, WMJ 118(2), 91 (1 case)

(2011): Dada MU+, Afr J Psychiatry (Johannesbg) 14(4), 316

Seizures 

(2003): Jain R+, J Dermatol 30(10), 713 (with cyclophosphamide)

Sleep related disorder 

(2016): Warris LT+, J Clin Oncol 34(19), 2287Pediatric

Somnolence (drowsiness) 

(2017): Nakashima K+, Jpn J Clin Oncol 47(9), 84013% (with aprepitant, olanzapine and palonosetron)

(2011): Hus M+, Ann Hematol 90(10), 116110% (with thalidomide)

Syncope 

(2013): Richardson PG+, Blood 122(14), 23319% (with bortezomib and panobinostat)

Vertigo / dizziness 

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2013): Gurung V+, Cochrane Database Syst Rev 6, CD000493 [REVIEW]

(2011): Hus M+, Ann Hematol 90(10), 116110% (with thalidomide)

Alanine aminotransferase (ALT) increased 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2013): Wang M+, Blood 122(18), 312214% (with carfilzomib and lenalidomide)

Alkaline phosphatase (ALP) increased 

(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)

Appetite decreased 

(2015): Gupta N+, J Hematol Oncol 8, 10319% (with lenalidomide and ixazomib)

Appetite increased 

(2016): Navari RM, Expert Opin Drug Saf 15(3), 343 [REVIEW]

Aspartate aminotransferase (AST) increased 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (3 cases) (with oxaliplatin)

Cushing's syndrome 

(2017): Franke V+, BMJ Case Rep Apr, EpubPediatric (in a herbal preparation)

(2012): Dutta D+, J Clin Res Pediatr Endocrinol 4(3), 157 (from intranasal)

Dehydration  

(2018): Hansen VL+, Clin Lymphoma Myeloma Leuk Mar, Epub ahead of print26% (grade 3 or 4) (with bortzomib and panobinostat)

(2014): Richardson PG+, Blood 123(12), 18265% (grade 3 or 4) (with pomalidomide)

(2013): Richardson PG+, Blood 122(14), 233116% (with bortezomib and panobinostat)

Diabetes mellitus 

(2016): Jeong Y+, Cancer Res Treat 48(4), 142920%

Hypercalcemia  

(2014): Richardson PG+, Blood 123(12), 18261% (grade 3 or 4) (with pomalidomide)

Hyperglycemia 

(2018): Sing EPC+, J Pediatr Hematol Oncol Apr, Epub ahead of print63%

(2017): Badros A+, Blood 130(10), 118925% (grade 3 or 4) (with pembrolizumab and pomalidomide)

(2016): Hatano Y+, BMJ Support Palliat Care 6(3), 331

(2016): Navari RM, Expert Opin Drug Saf 15(3), 343 [REVIEW]

(2013): Wang M+, Blood 122(18), 312227% (with carfilzomib and lenalidomide)

(2012): Jakubowiak AJ+, Blood 120(9), 180123% (low-dose / with carfilzomib and lenalidomide)

(2012): Lentzsch S+, Blood 119(20), 4608 (with bendamustine and lenalidomide)

(2012): Zhang YP+, Biomed Environ Sci 25(3), 311 (after intravitreal surgery)

Hypocalcemia 

(2014): Noriega Aldave AP+, J Med Case Rep 8, 353 (with bortezomib, lenalidomide and zoledronate)

Hypokalemia 

(2015): Gupta N+, J Hematol Oncol 8, 1037% (grade 3+) (with lenalidomide and ixazomib)

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2013): Richardson PG+, Blood 122(14), 233122% (with bortezomib and panobinostat)

(2013): Wang M+, Blood 122(18), 312225% (with carfilzomib and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195329% (with elotuzumab and lenalidomide)

Hyponatremia 

(2013): Wang M+, Blood 122(18), 312215% (with carfilzomib and lenalidomide)

Hypophosphatemia 

(2013): Richardson PG+, Blood 122(14), 23316% (with bortezomib and panobinostat)

(2013): Wang M+, Blood 122(18), 312239% (with carfilzomib and lenalidomide)

(2012): Jakubowiak AJ+, Blood 120(9), 180125% (low-dose / with carfilzomib and lenalidomide)

(2012): Jakubowiak AJ+, Br J Haematol 158(4), 47223% (with lenalidomide and perifosine)

Hypothyroidism 

(2017): Badros A+, Blood 130(10), 118910% (with pembrolizumab and pomalidomide)

Serum creatinine increased 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2014): Richardson PG+, Blood 123(12), 18263% (grade 3 or 4) (with pomalidomide)

Weight gain 

(2016): Navari RM, Expert Opin Drug Saf 15(3), 343 [REVIEW]

Weight loss 

(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)

Abdominal distension 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2013): Richardson PG+, Blood 122(14), 233120% (with bortezomib and panobinostat)

Abdominal pain 

(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)

(2014): Hamada S+, Support Care Cancer 22(8), 21613% (with aprepitant and palonosetron)

(2013): Gurung V+, Cochrane Database Syst Rev 6, CD000493 [REVIEW]

(2013): Richardson PG+, Blood 122(14), 233116% (with bortezomib and panobinostat)

(1997): Borgna-Pignatti C+, J Pediatr 130(1), 13-6

Cholangitis 

(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (1 case) (with oxaliplatin)

Constipation 

(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)

(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)

(2017): Moreau P+, Blood 130(22), 239241% (with bortezomib and venetoclax)

(2016): Kobayashi K+, J Clin Oncol 34(26_suppl), 226 (mild) (with aprepitant and palonosetron)

(2016): Yang CK+, Biomed J 39(1), 6043% (with aprepitant and palonosetron)

(2015): Usmani SZ+, Blood Cancer J 5, e33450% (with bortezomib, elotuzumab and lenalidomide)

(2014): Takeshima N+, Support Care Cancer 22(11), 2891 (3 cases) (with aprepitant and palonosetron)

(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)

(2013): Wang M+, Blood 122(18), 312227% (with carfilzomib and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195339% (with elotuzumab and lenalidomide)

(2011): Hus M+, Ann Hematol 90(10), 116114% (with thalidomide)

Diarrhea 

(2020): Palladini G+, Blood Apr, Epub ahead of print68% (with daratumumab, cyclophosphamide and bortezomib)

(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)

(2018): Hansen VL+, Clin Lymphoma Myeloma Leuk Mar, Epub ahead of print18% (grade 3 or 4) (with bortezomib and panobinostat)

(2018): Mikhael J+, Blood Cancer J 8(9) (with lenalidomide)

(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)

(2017): Moreau P+, Blood 130(22), 239246% (with bortezomib and venetoclax)

(2016): Mu S+, Eur J Clin Pharmacol 72(2), 153 (with bortezomib and panobinostat)

(2016): Richardson PG+, Blood 127(6), 713 (grade 3 or 4) (with bortezomib and panobinostat)

(2016): Richardson PG+, Expert Rev Clin Pharmacol 9(1), 35 [REVIEW]25% (grade 3 or 4) (with bortezomib and panobinostat)

(2015): Gupta N+, J Hematol Oncol 8, 10340% (with lenalidomide and ixazomib)

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2015): Richardson PG+, Lancet Haematol 2(12), e51666% (with elotuzumab and lenalidomide)

(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)

(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (2 cases) (with oxaliplatin)

(2014): San-Miguel JF+, Lancet Oncol 15(11), 11958% (grade 3 or 4) (with bortezomib)

(2014): Siegel DS+, Blood Cancer J 4, e18255% (with lenalidomide and vorinostat)

(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)

(2013): Richardson PG+, Blood 122(14), 233171% (with bortezomib and panobinostat)

(2013): Wang M+, Blood 122(18), 312258% (with carfilzomib and lenalidomide)

(2012): Jakubowiak AJ+, Br J Haematol 158(4), 47245% (with lenalidomide and perifosine)

(2012): Lonial S+, J Clin Oncol 30(16), 195350% (with elotuzumab and lenalidomide)

Dyspepsia 

(2018): Sing EPC+, J Pediatr Hematol Oncol Apr, Epub ahead of print24%

(2016): Navari RM, Expert Opin Drug Saf 15(3), 343 [REVIEW]

(2014): Roila F+, J Clin Oncol 32(2), 1018%

Eructation (belching) 

(2014): Zheng CR+, Am J Med 127(10), 1001 (4 cases)

Flatulence 

(2013): Richardson PG+, Blood 122(14), 233111% (with bortezomib and panobinostat)

Gastroesophageal reflux 

(2018): Sing EPC+, J Pediatr Hematol Oncol Apr, Epub ahead of print24%

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

Gastrointestinal bleeding 

(2010): Subedi BH+, Wilderness Environ Med 21(4), 345

Gastrointestinal disorder 

(2015): Korde N+, JAMA Oncol 1(6), 74692% (with carfilzomib and lenalidomide)

(2012): Chanan-Khan AA+, Int J Hematol 96(2), 254 (with lenalidomide)

(2012): Kumar S+, Blood 119(19), 4375 (with bortezomib, cyclophosphamide and lenalidomide)

Hepatotoxicity 

(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 79014% (with cisplatin, etoposide and ifosfamide)

(2015): Ding H+, Int J Hematol 102(2), 181 (with etoposide, methotrexate and pegaspargase)

(2014): Zhang Y+, Pathol Oncol Res 20(4), 98713–43% (with bortezomib and doxorubicin)

(2012): Miller RJ+, Can J Neurol Sci 39(4), 547 (with temozolomide)

Ileus 

(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (1 case) (with oxaliplatin)

Nausea 

(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)

(2017): Moreau P+, Blood 130(22), 239238% (with bortezomib and venetoclax)

(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 79066% (with cisplatin, etoposide and ifosfamide)

(2015): Gupta N+, J Hematol Oncol 8, 10316% (with lenalidomide and ixazomib)

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)

(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (2 cases) (with oxaliplatin)

(2013): Gurung V+, Cochrane Database Syst Rev 6, CD000493 [REVIEW]

(2013): Richardson PG+, Blood 122(14), 233160% (with bortezomib and panobinostat)

(2013): Wang M+, Blood 122(18), 312235% (with carfilzomib and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195343% (with elotuzumab and lenalidomide)

(2011): Hus M+, Ann Hematol 90(10), 11615% (with thalidomide)

Pancreatitis 

(2014): Keino D+, Rinsho Ketsueki (Japanese) 55(3), 327 (with bortezomib, doxorubicin and vincristine)

(2010): Vinklerova I+, Dig Dis Sci 55(10), 2977 (1 case)

Vomiting  

(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)

(2016): Aljebab F+, Arch Dis Child 101(4), 365 [REVIEW]

(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 79066% (with cisplatin, etoposide and ifosfamide)

(2015): Gupta N+, J Hematol Oncol 8, 10321% (with lenalidomide and ixazomib)

(2015): Usmani SZ+, Blood Cancer J 5, e33450% (with bortezomib, elotuzumab and lenalidomide)

(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (1 case) (with oxaliplatin)

(2011): Hus M+, Ann Hematol 90(10), 11612% (with thalidomide)

Urinary tract infection 

(2014): Richardson PG+, Blood 123(12), 18269% (grade 3 or 4) (with pomalidomide)

Vulvovaginal burning 

(2018): Dylla L+, Prehosp Emerg Care Feb, Epub ahead of print

Anemia 

(2018): Li CS+, Zhongguo Shi Yan Xue Ye Xue Za Zhi 26(3), 836 (with bortezomib and thalidomide)

(2018): Mikhael J+, Blood Cancer J 8(9) (with lenalidomide)

(2018): Sonbol MB+, Leuk Lymphoma Jan, Epub ahead of print28% (grade 3+) (with bortezomib, cyclophosphamide and rituximab)

(2017): Boccia RV+, Clin Lymphoma Myeloma Leuk 17(7), 43325% (grade 3+) (with carfilzomib and cyclophosphamide)

(2017): Hou J+, J Hematol Oncol 10(1), 1372–26% (grade 3 or 4) (with lenalidomide)

(2017): Lu J+, Br J Haematol 176(5), 74319% (grade 3 or 4) (with lenalidomide)

(2017): Moreau P+, Eur J Haematol 99(3), 19932% (grade 3 or 4) (with pomalidomide)

(2017): Moreau P+, Blood 130(22), 239215% (grade 3 or 4) (with bortezomib and venetoclax)

(2017): Zhang YP+, Eur J Haematol 99(6), 489 (with bortezomib)

(2016): Dimopoulos MA+, Lancet Oncol 17(1), 2710–14% (grade 3+) (with bortezomib or carfilzomib)

(2016): Du X+, BMC Cancer 16(1), 4611% (grade 3 or 4) (with lenalidomide)

(2016): Palumbo A+, N Engl J Med 375(8), 75416% (grade 3 or 4) (with bortezomib)

(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 79068% (with dexamethasone, etoposide and ifosfamide)

(2016): Plesner T+, Blood 128(14), 1821>5% (grade 3 or 4) (with daratumumab and lenalidomide)

(2016): Richardson PG+, Expert Rev Clin Pharmacol 9(1), 35 [REVIEW]20% (grade 3 or 4) (with bortezomib and panobinostat)

(2016): Suzuki K+, Cancer Sci 107(5), 65319% (grade 3 or 4) (with lenalidomide)

(2016): Wang JJ+, Medicine (Baltimore) 95(6), e278715% (grade 3 or 4) (with cisplatin and gemcitabine)

(2015): Ding H+, Int J Hematol 102(2), 18123% (grade 3 or 4) (with etoposide, methotrexate and pegaspargase)

(2015): Gupta N+, J Hematol Oncol 8, 1037% (grade 3+) (with lenalidomide and ixazomib)

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortzomib and palbociclib)

(2015): Shah JJ+, Blood 126(20), 2284 (with carfilzomib and pomalidomide)

(2014): Baz RC+, Am J Hematol 89(1), 6216% (grade 3 or 4) (with doxorubicin and lenalidomide)

(2014): Bringhen S+, Blood 124(1), 6311% (grade 3+) (with carfilzomib and cyclophosphamide)

(2014): Hopfinger G+, Ann Hematol 93(3), 4598% (grade 3+) (with lenalidomide and vorinostat)

(2014): Richardson PG+, Blood 123(12), 182622% (grade 3 or 4) (with pomalidomide)

(2014): Siegel DS+, Blood Cancer J 4, e18258% (with lenalidomide and vorinostat)

(2013): Fouquet G+, Cancer 119(20), 36806% (grade 3–4) (with lenalidomide)

(2013): Hatano K+, Int J Clin Oncol 18(4), 704 (grade 3+ / 1 case) (with docetaxel and estramustine)

(2013): Lamm W+, J Cancer Res Clin Oncol 139(10), 177117% (grade 2+) (with cytarabine, oxaliplatin and rituximab)

(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)

(2013): Miguel JS+, Lancet Oncol 14(11), 105537% (grade 3 or 4) (high-dose)

(2013): Richardson PG+, Blood 122(14), 233147% (with bortezomib and panobinostat)

(2013): San Miguel J+, Lancet Oncol 14(11), 105537% (grade 3 or 4) (high-dose)

(2013): Wang M+, Blood 122(18), 312233% (with carfilzomib and lenalidomide)

(2012): Berenson JR+, Leukemia 26(7), 167530% (with bortezomib, doxorubicin and lenalidomide)

(2012): Chanan-Khan AA+, Int J Hematol 96(2), 254 (with lenalidomide)

(2012): Jakubowiak AJ+, Blood 120(9), 180121% (low-dose / with carfilzomib and lenalidomide)

(2012): Lentzsch S+, Blood 119(20), 4608 (with bendamustine and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195346% (with elotuzumab and lenalidomide)

Coagulopathy 

(2016): Zhang L+, Oncotarget 7(34), 5572158% (with cisplatin, gemcitabine and pegaspargase)

Eosinophilia 

(2014): Sekiguchi Y+, Indian J Hematol Blood Transfus 30(Suppl 1), 264 [REVIEW] (with lenalidomide)

Febrile neutropenia 

(2019): Tanaka K+, Acta Haematol 141(2), 111 (with cyclophosphamide and bortezomib)4 cases (with cyclophosphamide and bortezomib)

(2017): Sangha R+, J Drug Assess 6(1), 10 (2 cases) (with cisplatin, gemcitabine, inotuzumab ozogamicin and rituximab)

(2014): Baz RC+, Am J Hematol 89(1), 629% (grade 3 or 4) (with doxorubicin and lenalidomide)

(2014): Richardson PG+, Blood 123(12), 18263% (grade 3 or 4) (with pomalidomide)

(2012): Chanan-Khan AA+, Int J Hematol 96(2), 254 (with lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 19537% (with elotuzumab and lenalidomide)

(2012): Zaja F+, Haematologica 97(3), 41612% (with lenalidomide)

(2011): Park BB+, Invest New Drugs 29(1), 1542% (with gemcitabine, ifosfamide and oxaliplatin)

Granulocytopenia 

(2018): Li CS+, Zhongguo Shi Yan Xue Ye Xue Za Zhi 26(3), 836 (with bortezomib and thalidomide)

Hematological adverse effect 

(2019): Tanaka K+, Acta Haematol 141(2), 1111 case (grade 4 ) (with cyclophosphamide and bortezomib)

Hemoglobin decreased 

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2013): Wang M+, Blood 122(18), 31228% (with carfilzomib and lenalidomide)

Hemorrhage 

(2014): Benjamini O+, Am J Hematol 89(3), 282 (grade 3 or 4) (in hyper CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone) plus dasatinib)

Hemotoxicity 

(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)

(2017): Badros A+, Blood 130(10), 118940% (grade 3 or 4) (with pembrolizumab and pomalidomide)

(2017): Rosenthal A+, Am J Hematol 92(5), 467 (with cyclophosphamide, lenalidomide and rituximab)

(2016): Liu HB+, Zhongguo Shi Yan Xue Ye Xue Za Zhi (Chinese) 24(2), 498 (4 cases) (with lenalidomide)

(2015): Kim HJ+, Blood Res 50(1), 7 [REVIEW] (with lenalidomide)

(2015): Rodon P+, Haematologica 100(2), e56 (with bendamustine and bortezomib)

(2012): Kumar S+, Blood 119(19), 4375 (with bortezomib, cyclophosphamide and lenalidomide)

(2012): Kumar SK+, Blood 119(21), 4860 (with cyclophosphamide and lenalidomide)

Leukocytopenia (leukopenia) 

(2018): Sonbol MB+, Leuk Lymphoma Jan, Epub ahead of print33% (grade 3+) (with bortezomib, cyclophosphamide and rituximab)

(2017): Boccia RV+, Clin Lymphoma Myeloma Leuk 17(7), 43313% (grade 3+) (with carfilzomib and cyclophosphamide)

(2017): Einsele H+, Br J Haematol 179(4), 58631% (grade 3+) (with bortezomib and cyclophosphamide)

(2016): Zhang L+, Oncotarget 7(34), 5572158% (grade 3 or 4) (with cisplatin, gemcitabine and pegaspargase)

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2015): Usmani SZ+, Blood Cancer J 5, e33450% (with bortezomib, elotuzumab and lenalidomide)

(2014): Hopfinger G+, Ann Hematol 93(3), 45915% (grade 3+) (with lenalidomide and vorinostat)

(2014): Richardson PG+, Blood 123(12), 182610% (grade 3 or 4) (with pomalidomide)

(2013): Wang M+, Blood 122(18), 312221% (with carfilzomib and lenalidomide)

(2012): Jakubowiak AJ+, Br J Haematol 158(4), 47213% (with lenalidomide and perifosine)

(2012): Kim SJ+, Invest New Drugs 30(1), 368 (with alemtuzumab, cisplatin and cytarabine)

(2012): Zaja F+, Haematologica 97(3), 41625% (with dexamethasone)

Leukocytosis (elevated white blood cell (WBC) count) 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

Lymphopenia (lymphocytopenia) 

(2016): Richardson PG+, Blood 127(6), 713 (grade 3 or 4) (with bortezomib and panobinostat)

(2015): Korde N+, JAMA Oncol 1(6), 746100% (with carfilzomib and lenalidomide)

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2015): Richardson PG+, Lancet Haematol 2(12), e51621% (grade 3 or 4) (with elotuzumab and lenalidomide)

(2015): Usmani SZ+, Blood Cancer J 5, e33466% (with bortezomib, elotuzumab and lenalidomide)

(2014): Craig M+, Br J Haematol 166(6), 920 (with bortezomib, cyclophosphamide, prednisone and rituximab)

(2014): Richardson PG+, Blood 123(10), 146111% (grade 3 or 4) (with bortezomib and lenalidomide)

(2014): Richardson PG+, Blood 123(12), 18267% (grade 3 or 4) (with pomalidomide)

(2014): San-Miguel JF+, Lancet Oncol 15(11), 119540% (grade 3 or 4) (with bortezomib)

(2013): Wang M+, Blood 122(18), 312252% (with carfilzomib and lenalidomide)

(2010): Richardson PG+, Blood 116(5), 67914% (with lenalidomide and bortezomib)

Myelosuppression (myelotoxicity) 

(2016): Pan Z+, Int J Cancer 139(8), 1864 (with methotrexate and radiotherapy)

(2014): Li M+, Leuk Lymphoma 55(7), 1578 (with bleomysin, cyclophosphamide, cytarabine and vindesine)

(2013): Gras J, Drugs Today (Barc) 49(9), 555 [REVIEW] (with pomalidomide)

(2013): Leleu X+, Blood 121(11), 1968 (with pomalidomide)

(2011): Lacy MQ+, Blood 118(11), 2970 (low dose / with pomalidomide)

Neutropenia 

(2018): Cohen A+, Br J Haematol 180(1), 6059% (grade 3+) (with doxorubicin and pomalidomide)

(2018): Dimopoulos MA+, Eur J Cancer 106, 8931% (with ixazomib and cyclophosphamide)

(2018): Sonbol MB+, Leuk Lymphoma Jan, Epub ahead of print38% (grade 3+) (with bortezomib, cyclophosphamide and rituximab)

(2017): Boccia RV+, Clin Lymphoma Myeloma Leuk 17(7), 43319% (grade 3+) (with carfilzomib and cyclophosphamide)

(2017): Hou J+, J Hematol Oncol 10(1), 1372–19% (grade 3 or 4) (with lenalidomide)

(2017): Itai S+, J Pharm Health Care Sci 3, 3

(2017): Lu J+, Br J Haematol 176(5), 74325% (grade 3 or 4) (with lenalidomide)

(2017): Moreau P+, Eur J Haematol 99(3), 19956% (grade 3 or 4) (with pomalidomide)

(2017): Paludo J+, Br J Haematol 179(1), 9820% (grade 3+) (with cyclophosphamide and rituximab)

(2017): Richardson PG+, Leukemia 31(12), 269544% (grade 3 or 4) (with bortezomib and pomalidomide)

(2017): Sangha R+, J Drug Assess 6(1), 1069% (with cisplatin, gemcitabine, inotuzumab ozogamicin and rituximab)

(2017): Tanaka N+, Jpn J Clin Oncol 47(3), 247 (with docetaxel)

(2017): Zhang YP+, Eur J Haematol 99(6), 489 (with bortezomib)

(2016): Du X+, BMC Cancer 16(1), 4620% (grade 3 or 4) (with lenalidomide)

(2016): Mateos MV+, Lancet Oncol 17(8), 11275% (grade 3) (with lenalidomide)

(2016): Palumbo A+, N Engl J Med 375(8), 7544% (grade 3 or 4) (with bortezomib)

(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 79085% (with cisplatin, etoposide and ifosfamide)

(2016): Plesner T+, Blood 128(14), 1821>5% (grade 3 or 4) (with daratumumab and lenalidomide)

(2016): Richardson PG+, Blood 127(6), 713 (grade 3 or 4) (with bortezomib and panobinostat)

(2016): Richardson PG+, Expert Rev Clin Pharmacol 9(1), 35 [REVIEW]35% (grade 3 or 4) (with bortezomib and panobinostat)

(2016): Suzuki K+, Cancer Sci 107(5), 65323% (grade 3 or 4) (with lenalidomide)

(2016): Wang JJ+, Medicine (Baltimore) 95(6), e278734% (grade 3 or 4) (with cisplatin and gemcitabine)

(2015): Ding H+, Int J Hematol 102(2), 18146% (grade 3 or 4) (with etoposide, methotrexate and pegaspargase)

(2015): Gupta N+, J Hematol Oncol 8, 10319% (with lenalidomide and ixazomib)

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2015): Richardson PG+, Lancet Haematol 2(12), e51619% (grade 3 or 4) (with elotuzumab and lenalidomide)

(2015): Tsukada N+, Rinsho Ketsueki 56(8), 1069 (grade 4 / 2 cases) (with bortezomib and cyclophosphamide)

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (4 cases) (with oxaliplatin)

(2014): Baz RC+, Am J Hematol 89(1), 6249% (grade 3 or 4) (with doxorubicin and lenalidomide)

(2014): Bringhen S+, Blood 124(1), 6320% (grade 3+) (with carfilzomib and cyclophosphamide)

(2014): Cook G+, Lancet Oncol 15(8), 87443% (with bortezomib and doxorubicin)

(2014): Craig M+, Br J Haematol 166(6), 920 (with bortezomib, cyclophosphamide, prednisone and rituximab)

(2014): Hopfinger G+, Ann Hematol 93(3), 4598% (grade 3+) (with lenalidomide and vorinostat)

(2014): Richardson PG+, Blood 123(10), 146142% (with bortezomib and lenalidomide)

(2014): Richardson PG+, Blood 123(12), 182641% (grade 3 or 4) (with pomalidomide)

(2013): Fouquet G+, Cancer 119(20), 368016% (grade 3–4) (with lenalidomide)

(2013): Hatano K+, Int J Clin Oncol 18(4), 704 (grade 3+ / 1 case) (with docetaxel and estramustine)

(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)

(2013): Miguel JS+, Lancet Oncol 14(11), 105516% (grade 3 or 4) (high-dose)

(2013): Richardson PG+, Blood 122(14), 233118% (with bortezomib and panobinostat)

(2013): San Miguel J+, Lancet Oncol 14(11), 105516% (grade 3 or 4) (high-dose)

(2013): San-Miguel JF+, J Clin Oncol 31(29), 369647–64% (grade 3 or 4) (with bortezomib and panobinostat)

(2013): Wang M+, Blood 122(18), 312237% (with carfilzomib and lenalidomide)

(2012): Berenson JR+, Leukemia 26(7), 167535% (with bortezomib, doxorubicin and lenalidomide)

(2012): Jakubowiak AJ+, Blood 120(9), 180117% (low-dose / with carfilzomib and lenalidomide)

(2012): Jakubowiak AJ+, Br J Haematol 158(4), 47226% (with lenalidomide and perifosine)

(2012): Lentzsch S+, Blood 119(20), 4608 (with bendamustine and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195339% (with elotuzumab and lenalidomide)

(2012): Zaja F+, Haematologica 97(3), 41653% (with lenalidomide)

(2011): Park BB+, Invest New Drugs 29(1), 154 (with gemcitabine, ifosfamide and oxaliplatin)

(2010): Richardson PG+, Blood 116(5), 6799% (with lenalidomide and bortezomib)

Platelets decreased 

(2015): Gupta N+, J Hematol Oncol 8, 10312% (with lenalidomide and ixazomib)

Prothrombin time increased  

(2016): Zhang L+, Oncotarget 7(23), 5572150% (with cisplatin, gemcitabine and pegaspargase)

Sepsis 

(2014): Richardson PG+, Blood 123(12), 18265% (grade 3 or 4) (with pomalidomide)

(2013): Richardson PG+, Blood 122(14), 23316–9% (with bortezomib and panobinostat)

(2012): Teoh G+, Clin Lymphoma Myeloma Leuk 12(2), 118 (with thalidomide and zoledronic acid)

Thrombocytopenia 

(2018): Hansen VL+, Clin Lymphoma Myeloma Leuk Mar, Epub ahead of print47% (grade 3 or 4) (with bortezomib and panobinostat)

(2018): Iida S+, Cancer Sci Feb, Epub ahead of print55% (grade 3 or 4) (with bortezomib)

(2018): Siegel DS+, J Clin Oncol Jan, Epub ahead of print15% (grade 3+) (with lenalidomide)

(2018): Sonbol MB+, Leuk Lymphoma Jan, Epub ahead of print29% (grade 3+) (with bortezomib, cyclophosphamide and rituximab)

(2018): Terpos E+, Eur J Haematol 100(1), 109–22% (grade 3+) (with bortezomib)

(2017): Einsele H+, Br J Haematol 179(4), 5867% (grade 3+) (with bortezomib and cyclophosphamide)

(2017): Hou J+, J Hematol Oncol 10(1), 1375–14% (grade 3 or 4) (with lenalidomide)

(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)

(2017): Moreau P+, Eur J Haematol 99(3), 19926% (grade 3 or 4) (with pomalidomide)

(2017): Moreau P+, Blood 130(22), 239229% (grade 3 or 4) (with bortezomib and venetoclax)

(2017): Paludo J+, Br J Haematol 179(1), 987% (grade 3+) (with cyclophosphamide and rituximab)

(2017): Richardson PG+, Leukemia 31(12), 269526% (grade 3 or 4) (with bortezomib and pomalidomide)

(2017): Sangha R+, J Drug Assess 6(1), 1085% (with cisplatin, gemcitabine, inotuzumab ozogamicin and rituximab)

(2017): Zhang YP+, Eur J Haematol 99(6), 489 (with bortezomib)

(2016): Dimopoulos MA+, Lancet Oncol 17(1), 278–9% (grade 3+) (with bortezomib or carfilzomib)

(2016): Mu S+, Eur J Clin Pharmacol 72(2), 153 (with bortezomib and panobinostat)

(2016): Palumbo A+, N Engl J Med 375(8), 75433% (grade 3 or 4) (with bortezomib)

(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 79041% (with cisplatin, etoposide and ifosfamide)

(2016): Plesner T+, Blood 128(14), 1821>5% (grade 3 or 4) (with daratumumab and lenalidomide)

(2016): Richardson PG+, Expert Rev Clin Pharmacol 9(1), 35 [REVIEW]67% (grade 3 or 4) (with bortezomib and panobinostat)

(2016): Richardson PG+, Blood 127(6), 713 (grade 3 or 4) (with bortezomib and panobinostat)

(2016): Shah JJ+, Blood Cancer J 6, e396 (grade 4) (with bortezomib, lenalidomide and siltuximab)

(2016): Shimazaki C+, Int J Hematol 103(1), 7947% (with bortezomib and melphalan)

(2016): Wang JJ+, Medicine (Baltimore) 95(6), e278720% (grade 3 or 4) (with cisplatin and gemcitabine)

(2016): Zhang L+, Oncotarget 7(34), 5572146% (grade 3 or 4) (with cisplatin, gemcitabine and pegaspargase)

(2015): Ding H+, Int J Hematol 102(2), 18131% (grade 3 or 4) (with etoposide, methotrexate and pegaspargase)

(2015): Gupta N+, J Hematol Oncol 8, 10319% (with lenalidomide and ixazomib)

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2015): Usmani SZ+, Blood Cancer J 5, e33450% (with bortezomib, elotuzumab and lenalidomide)

(2014): Baz RC+, Am J Hematol 89(1), 627% (grade 3 or 4) (with doxorubicin and lenalidomide)

(2014): Cook G+, Lancet Oncol 15(8), 87451% (with bortezomib and doxorubicin)

(2014): Craig M+, Br J Haematol 166(6), 920 (with bortezomib, cyclophosphamide, prednisone and rituximab)

(2014): Hopfinger G+, Ann Hematol 93(3), 45923% (grade 3+) (with lenalidomide and vorinostat)

(2014): Ludwig H+, Blood 123(7), 98538% (grade 3 or 4) (with bendamustine and bortezomib)

(2014): Richardson PG+, Blood 123(10), 146122% (grade 3 or 4) (with bortezomib and lenalidomide)

(2014): Richardson PG+, Blood 123(12), 182619% (grade 3 or 4) (with pomalidomide)

(2014): San-Miguel JF+, Lancet Oncol 15(11), 119531% (grade 3 or 4) (with bortezomib)

(2014): Zhang Y+, Pathol Oncol Res 20(4), 98713–38% (with bortezomib and doxorubicin)

(2013): Fouquet G+, Cancer 119(20), 36806% (grade 3–4) (with lenalidomide)

(2013): Lamm W+, J Cancer Res Clin Oncol 139(10), 177133% (grade 2+) (with cytarabine, oxaliplatin and rituximab)

(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)

(2013): Miguel JS+, Lancet Oncol 14(11), 105526% (grade 3 or 4) (high-dose)

(2013): Richardson PG+, Blood 122(14), 233166% (with bortezomib and panobinostat)

(2013): San Miguel J+, Lancet Oncol 14(11), 105526% (grade 3 or 4) (high-dose)

(2013): San-Miguel JF+, J Clin Oncol 31(29), 369667–85% (grade 3 or 4) (with bortezomib and panobinostat)

(2013): Wang M+, Blood 122(18), 312231% (with carfilzomib and lenalidomide)

(2012): Berenson JR+, Leukemia 26(7), 167535% (with bortezomib, doxorubicin and lenalidomide)

(2012): Jakubowiak AJ+, Blood 120(9), 180117% (low-dose / with carfilzomib and lenalidomide)

(2012): Jakubowiak AJ+, Br J Haematol 158(4), 47216% (with lenalidomide and perifosine)

(2012): Lentzsch S+, Blood 119(20), 4608 (with bendamustine and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195325% (with elotuzumab and lenalidomide)

(2012): Zaja F+, Haematologica 97(3), 41622% (with lenalidomide)

(2010): Richardson PG+, Blood 116(5), 6796% (with lenalidomide and bortezomib)

Thrombosis 

(2010): Rajkumar SV+, Lancet Oncol 11 (1), 2926% (deep vein) (with lenalidomide)

(2010): Richardson PG+, Blood 116(5), 6796% (with lenalidomide and bortezomib)

Infusion-related reactions 

(2016): Mateos MV+, Br J Haematol 175(3), 44815% (with elotuzumab and thalidomide)

(2016): Palumbo A+, N Engl J Med 375(8), 75445% (with bortezomib and daratumumab)

Infusion-site reactions 

(2016): Plesner T+, Blood 128(14), 182156% (with daratumumab and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 1953 (with elotuzumab and lenalidomide)

Injection-site reaction 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

Arthralgia 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2013): Wang M+, Blood 122(18), 312225% (with carfilzomib and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195325% (with elotuzumab and lenalidomide)

(2003): Jain R+, J Dermatol 30(10), 71314% (with cyclophosphamide)

(1991): Weissman DE+, J Neurooncol 11(3), 235

Asthenia / fatigue 

(2020): Palladini G+, Blood Apr, Epub ahead of print54% (with daratumumab, cyclophosphamide and bortezomib)

(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)

(2018): Hansen VL+, Clin Lymphoma Myeloma Leuk Mar, Epub ahead of print31% (grade 3 or 4) (with bortezomib and panobinostat)

(2018): Li CS+, Zhongguo Shi Yan Xue Ye Xue Za Zhi 26(3), 836 (with bortezomib and thalidomide)

(2018): Mikhael J+, Blood Cancer J 8(9) (with lenalidomide)

(2018): Sonbol MB+, Leuk Lymphoma Jan, Epub ahead of print14% (grade 3+) (with bortezomib, cyclophosphamide and rituximab)

(2017): Berdeja JG+, Br J Haematol 177(2), 254 (with bendamustine and bortezomib)

(2016): Berenson JR+, Blood 127(26), 336011% (grade 3+) (with carfilzomib)

(2016): Mateos MV+, Lancet Oncol 17(8), 11276% (grade 3) (with lenalidomide)

(2016): Mateos MV+, Br J Haematol 175(3), 44835% (grade 3+) (with elotuzumab and thalidomide)

(2016): Richardson PG+, Expert Rev Clin Pharmacol 9(1), 35 [REVIEW]24% (grade 3 or 4) (with bortezomib and panobinostat)

(2016): Richardson PG+, Blood 127(6), 713 (grade 3 or 4) (with bortezomib and panobinostat)

(2015): Gupta N+, J Hematol Oncol 8, 10316% (with lenalidomide and ixazomib)

(2015): Kim HJ+, Blood Res 50(1), 7 [REVIEW] (with lenalidomide)

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2015): Ocio EM+, Haematologica 100(7), e289 (with panobinostat)

(2015): Richardson PG+, Lancet Haematol 2(12), e51656% (with elotuzumab and dexamethasone)

(2015): Usmani SZ+, Blood Cancer J 5, e334100% (with bortezomib, elotuzumab and lenalidomide)

(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (3 cases) (with oxaliplatin)

(2014): Baz RC+, Am J Hematol 89(1), 6214% (grade 3 or 4) (with doxorubicin and lenalidomide)

(2014): Richardson PG+, Blood 123(10), 146150% (with bortezomib and lenalidomide)

(2014): Richardson PG+, Blood 123(12), 182614% (grade 3 or 4) (with pomalidomide)

(2014): San-Miguel JF+, Lancet Oncol 15(11), 119512% (grade 3 or 4) (with bortezomib)

(2014): Siegel DS+, Blood Cancer J 4, e18255% (with lenalidomide and vorinostat)

(2014): Takeshima N+, Support Care Cancer 22(11), 2891 (3 cases) (with aprepitant and palonosetron)

(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)

(2013): Miguel JS+, Lancet Oncol 14(11), 10556% (grade 3 or 4) (high-dose)

(2013): Richardson PG+, Blood 122(14), 233120–69% (with bortezomib and panobinostat)

(2013): San Miguel J+, Lancet Oncol 14(11), 10556% (grade 3 or 4) (high-dose)

(2013): San-Miguel JF+, J Clin Oncol 31(29), 369620–30% (grade 3 or 4) (with bortezomib and panobinostat)

(2013): Wang M+, Blood 122(18), 312269% (with carfilzomib and lenalidomide)

(2012): Berenson JR+, Leukemia 26(7), 167540% (with bortezomib, doxorubicin and lenalidomide)

(2012): Jakubowiak AJ+, Br J Haematol 158(4), 47248% (with lenalidomide and perifosine)

(2012): Kumar S+, Blood 119(19), 4375 (with bortezomib, cyclophosphamide and lenalidomide)

(2012): Kumar SK+, Blood 119(21), 4860 (with cyclophosphamide and lenalidomide)

(2012): Lentzsch S+, Blood 119(20), 4608 (with bendamustine and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195321–61% (with elotuzumab and lenalidomide)

(2011): Hus M+, Ann Hematol 90(10), 116119% (with thalidomide)

(2010): Rajkumar SV+, Lancet Oncol 11 (1), 2915% (with lenalidomide)

(2010): Richardson PG+, Blood 116(5), 67964% (with lenalidomide and bortezomib)

(2005): Richardson PG+, N Engl J Med 352(24), 2487

(2003): Jain R+, J Dermatol 30(10), 71354% (with cyclophosphamide)

(1997): Borgna-Pignatti C+, J Pediatr 130(1), 13-6

(1993): Pasricha JS+, Int J Dermatol 32(10), 753

Back pain 

(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)

(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)

(2014): Richardson PG+, Blood 123(12), 182610% (grade 3 or 4) (with pomalidomide)

(2013): Wang M+, Blood 122(18), 312231% (with carfilzomib and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195325% (with elotuzumab and lenalidomide)

Bone loss 

(2018): Zhang L+, J Pharm Sci Nov, Epub ahead of print (passim)

Bone or joint pain 

(2013): Miguel JS+, Lancet Oncol 14(11), 10555% (grade 3 or 4) (high-dose)

(2013): San Miguel J+, Lancet Oncol 14(11), 10555% (grade 3 or 4) (high-dose)

(2005): Richardson PG+, N Engl J Med 352(24), 2487

(1994): Chan-Lam D+, Br J Haematol 86(1), 227

Muscle spasm 

(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)

(2015): Kim HJ+, Blood Res 50(1), 7 [REVIEW] (with lenalidomide)

(2015): Richardson PG+, Lancet Haematol 2(12), e51662% (with elotuzumab and lenalidomide)

(2013): Wang M+, Blood 122(18), 312239% (with carfilzomib and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195332% (with elotuzumab and lenalidomide)

Myalgia/Myositis/Myopathy/Myotoxicity 

(2014): Richardson PG+, Blood 123(12), 18264% (grade 3 or 4) (with pomalidomide)

(2006): Mentink LF+, Arch Dermatol 142(5), 570

(2005): Richardson PG+, N Engl J Med 352(24), 2487

(2001): Hardy JR+, Palliat Med 15(1), 3-8

(1995): Koehler PJ, Anticancer Drugs 6(1), 19-3 [REVIEW]

(1991): Dropcho EJ+, Neurology 41(8), 1235

Osteonecrosis 

(2014): Mondello P+, Springerplus 3, 123 [REVIEW] (with ibandronate and lenalidomide)

(2005): Burger B+, Pediatr Blood Cancer 44(3), 220

(2004): van den Berkmortel F+, Neth J Med 62(1), 23-7

(2001): Strauss AJ+, J Clin Oncol 19(12), 3066

(2001): van Schaardenburg D+, Ned Tijdschr Geneeskd 145(37), 1769 [REVIEW]

(2001): Virik K+, Int J Clin Pract 55(5), 344

(2000): Mattano LA Jr+, J Clin Oncol 18(18), 3262

(1999): Ojala AE+, Med Pediatr Oncol 32(1), 11-7

(1997): Ojala AE+, Med Pediatr Oncol 29(4), 260

(1997): Thornton MJ+, Clin Radiol 52(8), 607

(1994): Osebold WR+, Iowa Orthop J 14, 120

(1990): Murphy RG+, Cancer 65(8), 1717

(1984): Fast A+, J Neurosurg 61(5), 983

(1982): McCluskey J+, Br Med J (Clin Res Ed) 284(6312), 333

(1981): Black KA+, Aust N Z J Med 11(5), 521

Osteoporosis 

(2018): Zhang L+, J Pharm Sci Nov, Epub ahead of print (passim)

(2004): Raff H, Trends Endocrinol Metab 15(8), 351

(1999): Fuchs M+, HNO 47(7), 647

(1988): Kruse K+, Monatsschr Kinderheilkd 136(5), 237

Pain in extremities 

(2013): Wang M+, Blood 122(18), 312225% (with carfilzomib and lenalidomide)

Cataract <10%

(2018): Blanc J+, Graefes Arch Clin Exp Ophthalmol May, Epub ahead of print70%

(2018): Tufail A+, Clin Ophthalmol 12, 2519 [REVIEW]

(2018): Yoon YH+, Ophthalmologica Apr, Epub ahead of print16% (newly diagnosed)

(2017): Fassbender Adeniran JM+, Ocul Immunol Inflamm 25(6), 834 [REVIEW]

(2016): Korobelnik JF+, Graefes Arch Clin Exp Ophthalmol 254(12), 230740% (progression)

(2014): Lambiase A+, Drugs Today (Barc) 50(3), 239

(2003): Jain R+, J Dermatol 30(10), 713 (with cyclophosphamide)

(1994): Zheng Y+, Yan Ke Xue Bao 10(2), 102

(1989): Mohan R+, Indian J Ophthalmol 37(1), 13-6

(1986): Bluming AZ+, J Clin Oncol 4(2), 221

Conjunctival hemorrhage >10%

(2014): Dang Y+, Drug Des Devel Ther 8, 1441 (mild)

Conjunctivitis 

(1995): Valdivieso R+, J Investig Allergol Clin Immunol 5(3), 171 (1 case) (with paramethasone)

Glaucoma 

(2014): Lambiase A+, Drugs Today (Barc) 50(3), 239

(2012): Mataftsi A+, J Cataract Refract Surg 38(10), 1719

(2006): Mentink LF+, Arch Dermatol 142(5), 570

(2003): Jain R+, J Dermatol 30(10), 713 (3 cases) (with cyclophosphamide)

(1999): Tan DT+, Ophthalmology 106(2), 223

(1995): Kong L+, Yan Ke Xue Bao 11(1), 53-6

(1993): Aggarwal RK+, Eye 7, 664

(1993): Kong LX, Zhonghua Yan Ke Za Zhi 29(3), 151

(1989): Mohan R+, Indian J Ophthalmol 37(1), 13-6

Intraocular pressure increased >10%

(2018): Blanc J+, Graefes Arch Clin Exp Ophthalmol May, Epub ahead of print55%

(2018): Li X+, Graefes Arch Clin Exp Ophthalmol 256(1), 59

(2018): Tufail A+, Clin Ophthalmol 12, 2519 [REVIEW]19%

(2018): Yoon YH+, Ophthalmologica Apr, Epub ahead of print35%

(2017): Eter N+, Graefes Arch Clin Exp Ophthalmol 255(1), 77

(2017): Malcles A+, Retina 37(4), 75310% (transient)

(2017): Malcles A+, Retina 37(7), 135229%

(2016): Korobelnik JF+, Graefes Arch Clin Exp Ophthalmol 254(12), 230734%

(2016): Matonti F+, Eur J Ophthalmol 26(5), 45413%

(2016): Novais EA+, J Ophthalmol Sep, Epub23%

(2015): Sheu SJ+, J Ocul Pharmacol Ther 31(8), 46111%

(2014): Ford JA+, BMJ Open 4(2), e004120 [REVIEW]

(2012): Chen M+, Curr Med Res Opin 28(3), 385 (with tobramycin)

(2008): White EM+, Curr Med Res Opin 24(1), 287

Ocular adverse effect 

(2016): Hoerauf H+, Am J Ophthalmol 169, 25887%

Ocular hypertension <10%

(2017): Fassbender Adeniran JM+, Ocul Immunol Inflamm 25(6), 834

(2015): Pelegrin L+, Eye (Lond) 29(7), 94348%

(2013): Kiddee W+, Surv Ophthalmol 58(4), 291 [REVIEW]11–15%

(2001): Dinning WJ+, Ophthalmology 108(10), 1715

(2000): Ng JS+, Ophthalmology 107(11), 2097

(1999): Deng Y+, Hua Xi Yi Ke Da Xue Xue Bao 30(2), 205

Ocular keratitis 

(2003): Davidson RS+, J Glaucoma 12(1), 23-6

Ocular pain <10%

(2014): Dang Y+, Drug Des Devel Ther 8, 1441 (mild)

(1999): Deng Y+, Hua Xi Yi Ke Da Xue Xue Bao 30(2), 205

(1997): Kwok AK+, Ophthalmology 104(12), 2112

(1995): Clark AF+, Invest Ophthalmol Vis Sci 36(2), 478

(1986): Kass M+, Am J Ophthalmol 102(2), 159

(1984): Stewart RH+, Curr Eye Res 3(6), 835

Retinopathy 

(1995): Ramanathan R+, J Perinatol 15(3), 178 (12 cases)

Vision blurred 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2013): Demirhan A+, Aesthetic Plast Surg 37(6), 1100 (with pregabalin)

(2003): Jain R+, J Dermatol 30(10), 7139% (with cyclophosphamide)

Visual halos 

(1999): Deng Y+, Hua Xi Yi Ke Da Xue Xue Bao 30(2), 205

Vitreous hemorrhage 

(2018): Tufail A+, Clin Ophthalmol 12, 2519 [REVIEW]3%

Ototoxicity 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(1998): Abello P+, Acta Otorrinolaringol Esp 49(5), 353

(1998): Arditi M+, Pediatrics 102(5), 1087

(1994): Syrogiannopoulos GA+, J Infect Dis 169(4), 853

Tinnitus 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

Nephrotoxicity 

(2017): Boccia RV+, Clin Lymphoma Myeloma Leuk 17(7), 43313% (grade 3+) (with carfilzomib and cyclophosphamide)

(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 790 (1 case) (with cisplatin, etoposide and ifosfamide)

Renal failure 

(2018): Siegel DS+, J Clin Oncol Jan, Epub ahead of print3% (grade 3+) (with dexamethasone)

(2014): Richardson PG+, Blood 123(12), 18265% (grade 3 or 4) (with pomalidomide)

Tumor lysis syndrome 

(2017): Khan F+, Oxf Med Case Reports 2017(5)

(2008): McDonnell C+, Anaesthesia 63(6), 652 (fatal)Fatal

(2008): Osthaus WA+, Paediatr Anaesth 18(3), 268

Cough 

(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)

(2014): Siegel DS+, Blood Cancer J 4, e18245% (with lenalidomide and vorinostat)

(2013): Wang M+, Blood 122(18), 312240% (with carfilzomib and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195321% (with elotuzumab and lenalidomide)

Dyspnea 

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

(2015): Shah JJ+, Blood 126(20), 2284 (with carfilzomib and pomalidomide)

(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)

(2014): Richardson PG+, Blood 123(12), 182613% (grade 3 or 4) (with pomalidomide)

(2013): Wang M+, Blood 122(18), 312237% (with carfilzomib and lenalidomide)

Flu-like syndrome 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

Nasopharyngitis 

(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)

Pleural effusion 

(2014): Benjamini O+, Am J Hematol 89(3), 282 (grade 3 or 4) (in hyper CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone) plus dasatinib)

Pneumonia 

(2017): Badros A+, Blood 130(10), 118915% (grade 3 or 4) (with pembrolizumab and pomalidomide)

(2017): Kwon J+, Cancer Med 6(1), 100 (fatal / 1 case)Fatal (with cyclophosphamide and thalidomide)

(2016): Dimopoulos MA+, Lancet Oncol 17(1), 277–8% (grade 3+) (with bortezomib or carfilzomib)

(2016): Shah JJ+, Blood Cancer J 6, e396 (grade 3) (with bortezomib, lenalidomide and siltuximab)

(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (1 case) (with oxaliplatin)

(2014): Keino D+, Rinsho Ketsueki (Japanese) 55(3), 327 (with bortezomib, doxorubicin and vincristine)

(2014): Richardson PG+, Blood 123(12), 182622% (grade 3 or 4) (with pomalidomide)

(2013): Miguel JS+, Lancet Oncol 14(11), 10558% (grade 3 or 4) (high-dose)

(2013): Richardson PG+, Blood 122(14), 233116% (with bortezomib and panobinostat)

(2013): San Miguel J+, Lancet Oncol 14(11), 10558% (grade 3 or 4) (high-dose)

(2013): Wang M+, Blood 122(18), 312217% (with carfilzomib and lenalidomide)

(2012): Berenson JR+, Leukemia 26(7), 167515% (with bortezomib, doxorubicin and lenalidomide)

(2012): Lonial S+, J Clin Oncol 30(16), 195314% (with elotuzumab and lenalidomide)

(2010): Rajkumar SV+, Lancet Oncol 11 (1), 2916% (with lenalidomide)

Pneumonitis 

(2017): Badros A+, Blood 130(10), 118913% (with pembrolizumab and pomalidomide)

(2013): Hatano K+, Int J Clin Oncol 18(4), 704 (grade 3+ / 4 cases) (with docetaxel and estramustine)

Pulmonary toxicity 

(2012): Lonial S+, J Clin Oncol 30(16), 19537% (with elotuzumab and lenalidomide)

Stridor 

(2012): Lonial S+, J Clin Oncol 30(16), 1953 (with elotuzumab and lenalidomide)

Upper respiratory tract infection 

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2013): Mateos MV+, N Engl J Med 369(5), 438 (fatal / 1 case)Fatal (with lenalidomide)

(2013): Wang M+, Blood 122(18), 312244% (with carfilzomib and lenalidomide)

Adverse effects 

(2018): Soyer N+, Turk J Med Sci 48(4), 77758% (with lenalidomide)

(2017): Patel P+, Br J Clin Pharmacol 83(10), 2148 [REVIEW] (pharmacokinetic interaction with aprepitant or fosaprepitant)

(2016): Berdeja J+, Clin Lymphoma Myeloma Leuk 16(3), 129 (with elotuzumab and lenalidomide)

(2016): Liu HB+, Zhongguo Shi Yan Xue Ye Xue Za Zhi (Chinese) 24(2), 498 (4 cases) (gastrointestinal / with lenalidomide)

(2016): Prud'homme M+, Can J Neurol Sci 43(2), 284

(2015): Cibeira MT+, Br J Haematol 170(6), 80414% (with cyclophosphamide and lenalidomide)

(2015): Sharma A+, Perspect Clin Res 6(2), 109<1%

(2015): Stewart AK+, N Engl J Med 372(2), 14281% (grade 3+) (with lenalidomide)

(2014): Bringhen S+, Blood 124(1), 637% (grade 3+) (cardiopulmonary / with carfilzomib and cyclophosphamide)

(2014): Lazaryan A+, Am J Hematol 89(4), 349 (with doxorubicin, lenalidomide and vincristine)

(2014): Leiba M+, Br J Haematol 166(5), 702 [REVIEW]74% (grade 3 or 4) (with bortezomib and cyclophosphamide)

(2014): San-Miguel JF+, Lancet Oncol 15(11), 119542% (serious) (with bortezomib)

(2012): Kumar SK+, Blood 119(21), 4860 (gastrointestinal / with cyclophosphamide and lenalidomide)

(2005): Richardson PG+, N Engl J Med 352(24), 248760%

(2004): Borst F+, Ann Hematol 83(12), 764

(2004): May C+, Monaldi Arch Chest Dis 61(3), 162 [REVIEW]

(2004): Odd DE+, J Paediatr Child Health 40(5-6), 282

(2004): Palladini G+, Blood 103(8), 293611% (with melphalan)

(1998): Yeh TF+, Pediatrics 101(5), E7

(1986): Garden JM+, Arch Dermatol 122(9), 1007

Allergic reactions 

(2011): Hus M+, Ann Hematol 90(10), 11615% (with thalidomide)

(1989): Brambilla L+, Contact Dermatitis 21(4), 272

Death 

(2017): Kwon J+, Cancer Med 6(1), 100 (3 cases) (with cyclophosphamide and thalidomide)

(2014): Lazaryan A+, Am J Hematol 89(4), 349 (4 cases) (with doxorubicin, lenalidomide and vincristine)

(2013): Mateos MV+, N Engl J Med 369(5), 438 (1 case) (with lenalidomide)

(2013): Miguel JS+, Lancet Oncol 14(11), 10555% (high-dose)

(2013): San Miguel J+, Lancet Oncol 14(11), 10555% (high-dose)

(2008): McDonnell C+, Anaesthesia 63(6), 652Pediatric

(1994): Malik IA+, South Med J 87(3), 409

(1992): Heimdal K+, J Neurooncol 12(2), 141

(1992): O'Neil EA+, Arch Dis Child 67(1), 10-1

(1991): Friedenberg WR+, Am J Hematol 36(3), 171

(1990): Ferrara TB+, J Perinatol 10(2), 137

Hiccups 

(2018): Kim J+, Eur J Oncol Nurs 37, 23

(2017): Go SI+, Oncologist 22(11), 1354

(2017): Ioroi T+, Support Care Cancer Nov, Epub ahead of print48% (with aprepitant and palonosetron)

(2016): de Arriba Mendez JJ, Med Clin (Barc) (Spanish) 146(6), 284

(2016): Yang CK+, Biomed J 39(1), 6026% (with aprepitant and palonosetron)

(2015): El Abd O+, Pain Physician 18(3), 277

(2014): Hamada S+, Support Care Cancer 22(8), 216113% (with aprepitant and palonosetron)

(2012): Kang JH+, J Pain Symptom Manage 43(3), 625 (5 cases)

(2009): Gilbar P+, J Oncol Pharm Pract 15 (4), 233

(2005): Errante D+, Gut 54(10), 1503

(2005): Liaw CC+, J Pain Symptom Manage 30(4), 359

(2003): Jain R+, J Dermatol 30(10), 713 (9 cases) (with cyclophosphamide)

(2001): Eguchi F+, Gan To Kagaku Ryoho 28(10), 1423 (with ondansetron)

(2001): Horichi N+, Gan To Kagaku Ryoho 28(7), 953

(1999): Ross J+, West J Med 170(1), 51-2

(1998): Cersosimo RJ+, Cancer 82(2), 412

(1996): Sekine I+, Jpn J Clin Oncol 26(3), 164

(1993): Jaime Vazquez J, Hum Exp Toxicol 12(1), 52

(1982): LeWitt PA+, Ann Neurol 12(4), 405

Infection 

(2019): Tanaka K+, Acta Haematol 141(2), 1114 cases (grade 3–4) (with cyclophosphamide and bortezomib)

(2017): Lu J+, Br J Haematol 176(5), 74319% (grade 3 or 4) (with lenalidomide)

(2017): Moreau P+, Eur J Haematol 99(3), 19934% (grade 3 or 4) (with pomalidomide)

(2017): Palladini G+, Blood 129(15), 2120 (with pomalidomide)

(2017): Paludo J+, Br J Haematol 179(1), 983% (grade 3+) (with cyclophosphamide and rituximab)

(2016): Mateos MV+, Lancet Oncol 17(8), 11276% (grade 3) (with lenalidomide)

(2015): Ding H+, Int J Hematol 102(2), 18115% (with etoposide, methotrexate and pegaspargase)

(2015): Kim HJ+, Blood Res 50(1), 7 [REVIEW] (with lenalidomide)

(2015): Rodon P+, Haematologica 100(2), e56 (with bendamustine and bortezomib)

(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)

(2014): Benjamini O+, Am J Hematol 89(3), 282 (grade 3 or 4) (in hyper CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone) plus dasatinib)

(2014): Ludwig H+, Blood 123(7), 98523% (grades 3 to 5) (with bendamustine and bortezomib)

(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)

(2013): Voorhees PM+, Br J Haematol 161(3), 35757% (with siltuximab)

(2012): Zaja F+, Haematologica 97(3), 41612% (with lenalidomide)

(2004): Mantadakis E+, Pediatr Hematol Oncol 21(1), 27-3

(2003): Belgaumi AF+, Cancer 97(11), 289836%

(1999): Stoll BJ+, Pediatrics 104(5), e63

(1998): Hari P+, Indian J Pediatr 65(4), 557 [REVIEW]

(1998): Papile LA+, N Engl J Med 338(16), 1112

(1998): Thomas MC+, Int J Clin Pract 52(7), 520

(1995): Koehler PJ, Anticancer Drugs 6(1), 19-3 [REVIEW]

(1994): Keogh P+, Neurosurgery 34(2), 364

(1994): Sharada B+, Rheumatol Int 14(3), 91-4

(1991): Friedenberg WR+, Am J Hematol 36(3), 171

(1990): Ferrara TB+, J Perinatol 10(2), 137

(1990): Karnik R+, Wien Klin Wochenschr 102(1), 1-4

(1990): Ng PC+, Arch Dis Child 65(1 Spec No), 54-6

(1985): Moskopp D, Neurochirurgia (Stuttg) 28(3), 147

(1983): Hanks GW+, Postgrad Med J 59(697), 702

(1980): West BC+, Am J Ophthalmol 89(6), 854

Side effects 

(2001): Hamon I+, J Gynecol Obstet Biol Reprod (Paris) 30(6), S50 [REVIEW]

(1997): Kuhne T+, J Pediatr 130(1), 17-2

(1996): Ralls JE, Aust Fam Physician 25(5), 713



Adverse reactions attributed to entire drug class Antiemetic

Akathisia 

(2018): Rashid A+, Psychooncology 27(4), 1338 [REVIEW]5%

Adverse reactions attributed to entire drug class Corticosteroid, systemic

Bradycardia 

(2019): Duffy C+, J Pediatr Hematol Oncol Apr, Epub ahead of print98%Pediatric (with induction chemotherapy)

Neuropsychiatric disturbances 

(2020): Cole JL, Fed Pract 37(6), 260-267 [REVIEW]

Sleep disturbances 

(2020): Cole JL, Fed Pract 37(6), 260-267 [REVIEW]

Diabetes mellitus 

(2015): Satyanarayanasetty D+, J Clin Diagn Res 9(5), Epub

Osteoporosis 

(2015): Satyanarayanasetty D+, J Clin Diagn Res 9(5), Epub

Cataract 

(2015): Satyanarayanasetty D+, J Clin Diagn Res 9(5), Epub

Adverse effects 

(2017): Aljebab F+, PLoS One 12(1), Epub [REVIEW]Pediatric

Adverse reactions attributed to entire drug class Corticosteroid, topical

Acneiform eruption / acneiform dermatitis 

(2018): Shukla S+, Expert Opin Drug Saf 17(2), 179 [REVIEW]

(2016): Nagesh TS+, Indian J Dermatol 61(6), 618

Atrophy 

(2019): Ah YM+, Basic Clin Pharmacol Toxicol Apr, Epub ahead of print

(2018): Shukla S+, Expert Opin Drug Saf 17(2), 179 [REVIEW]

(2015): Barnes L+, Drug Saf 38(5), 493 [REVIEW]

Burning 

(2016): Nagesh TS+, Indian J Dermatol 61(6), 618

Erythema 

(2016): Nagesh TS+, Indian J Dermatol 61(6), 618

Pigmentation 

(2019): Ah YM+, Basic Clin Pharmacol Toxicol Apr, Epub ahead of print

(2018): Shukla S+, Expert Opin Drug Saf 17(2), 179 [REVIEW]

(2016): Nagesh TS+, Indian J Dermatol 61(6), 618

Pruritus (itching) 

(2016): Nagesh TS+, Indian J Dermatol 61(6), 618

Striae 

(2018): Shukla S+, Expert Opin Drug Saf 17(2), 179 [REVIEW]

(2016): Nagesh TS+, Indian J Dermatol 61(6), 618

Telangiectasia 

(2018): Shukla S+, Expert Opin Drug Saf 17(2), 179 [REVIEW]

Leukoplakia 

(2015): Vigarios E+, Ann Dermatol Venereol (French) 142(10), 572

Adverse effects 

(2016): Mehta AB+, Indian J Dermatol Venereol Leprol 82(4), 371 [REVIEW]

Adverse reactions attributed to entire drug class COVID-19 putative drug

Cutaneous adverse reaction  

(2020): Tursen U+, Dermatol Ther May, Epub ahead of print [REVIEW]

Cardiovascular adverse effect 

(2020): Carpenter A+, Front Cardiovasc Med 7, 85 [REVIEW]

(2020): Giudicessi JR+, Mayo Clin Proc May, Online ahead of print [REVIEW]

(2020): Naksuk N+, Eur Heart J Acute Cardiovasc Care May, Epub ahead of print [REVIEW]

(2020): Sarayani A+, Res Social Adm Pharm Apr, Epub ahead of print [REVIEW]

(2020): Zhang D+, Zhongguo Zhong Yao Za Zhi (Chinese) 45(10), 2275-2286 [REVIEW]

Neuropsychiatric disturbances 

(2020): García CAC+, Gen Hosp Psychiatry Jun, Online ahead of print [REVIEW]

Gastrointestinal disorder 

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print23%

Hepatic disorder 

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print14%

Thrombocytopenia 

(2020): Nham E+, Infect Chemother Apr, Epub ahead of print

Adverse effects 

(2020): Favilli A+, J Matern Fetal Neonatal Med Jun, Online ahead of print [REVIEW]

(2020): Griffiths G+, Trials 21(1), 544

(2020): Patil VM+, Life Sci May, Epub ahead of print [REVIEW]

(2020): Rhodes NJ+, medRxiv Jun, Preprint

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print38%

(2020): Svensson M, Lakartidningen (Swedish) Apr, 117

(2020): Wen CY+, Zhonghua Nei Ke Za Zhi (Chinese) May, Epub ahead of print

(2020): Zekarias A+, Drug Saf Sep, Online ahead of print [REVIEW]

(2020): Zhong H+, Pharmacol Res Apr, Epub ahead of print [REVIEW]

Page last updated 06/25/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top